- A study examining chromium excretion during pregnancy found that persistently elevated excretion in normal pregnancies seemed to be associated with a significant reduction in insulin sensitivity. In turn, it was speculated that enhanced chromium excretion had the potential to put a mother at increased risk of developing gestational or post-partum diabetes. Morris BW, Samaniego S, Fraser R, MacNeil S. Increased chromium excretion in pregnancy is associated with insulin resistant. Journal Trace Element Expert Medicine 2000; 13:389-96.
- Impairment of glucose tolerance induced by pregnancy may be associated with a low chromium status. Davidson IWF, Burt RL. Physiologic changes in plasma chromium of normal and pregnant woman; effect on glucose load. Am J Osbtet Gynecology 1973; 116:601-8.
- Chromium supplementation for gestational diabetic women improves glucose tolerance and lowers hyperinsulinemia. Lois Jovanovic, Mario Gutierrez, Charles M. Peterson. Chromium supplementation for women with gestational diabetes mellitus. J Trace Elem Exper Med 1999;12:91-97.
- Clinical trial proved that GT&F® can help reducing plasma glucose and plasma insulin. Dee Pei, Chang-Hsun Hsieh, Yi-Jen Hung, Jer-Chuang Li, Chien-Hsing Lee, Shi-Wen Kuo. The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Metabolism 2006; 55:923-927.
CLINICAL TRIAL
| GT&F® Significantly Reduce Plasma Glucose | GT&F® Significantly Reduced Plasma Insulin |
|---|---|
 |
 |
| After 16 weeks, fasting plasma glucose was significantly reduced in Type 2 Diabetes. |
After 16 weeks, fasting plasma insulin was significantly reduced in Type 2 Diabetes. |
